BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $186.26M rose 44.2% year over year, behind the +67.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.6% from the prior quarter. Over 3 fiscal years it compounded at +57.1% a year.
Context
- Selling, general & admin amounted to 110.6% of revenue in FY2025, down 19.6 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 13 analysts of $5.05B (+810.4%) for the fiscal year ending Dec 2026, a step up from the +92.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $186.26M+13.6% QoQ
- Last fiscal yearDec 2025
- $555.14M+92.1% YoY
- LTMJun 2026
- $669.78M+67.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 555.14M USD
- Year-over-year change
- +92.1%
- 4-year CAGR
- +30.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 555.14M | +92.1% |
| FY2024 | 2024-12-31 | 288.93M | +91.9% |
| FY2023 | 2023-12-31 | 150.59M | +5.2% |
| FY2022 | 2022-12-31 | 143.19M | -25.5% |
| FY2021 | 2021-12-31 | 192.21M | — |
Selling, General & Admin vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +67.8% is the 2nd highest of 11, against a peer median of +27.8%.
- Selling, general & admin amounts to 93.9% of revenue for BBIO, versus a peer median of 55.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $335.1B USD | +34325.1% | +15.8% | 32.6% | |
| LTM Jun 2026 | $1.32B USD | +22.1% | +16.3% | 27.4% | |
| LTM Jun 2026 | $669.78M USD | +67.8% | +57.1% | 93.9% | |
| LTM Sep 2026 | €598.18M EUR | +52.7% | +26.4% | 49.5% | |
| LTM Sep 2026 | $584.98M USD | +66.3% | +37.9% | 61.0% | |
| LTM Sep 2026 | $376.47M USD | +23.4% | +19.5% | 57.8% | |
| LTM Jun 2026 | $351.33M USD | +8.3% | +2.1% | 34.8% | |
| LTM Mar 2026 | $350.27M USD | +5.7% | +7.9% | 52.3% | |
| LTM Sep 2026 | $198.39M USD | +32.1% | +60.5% | 34804.4% | |
| LTM Jun 2026 | $139.03M USD | +19.2% | +2.4% | 3857.6% | |
| LTM Mar 2026 | $39.04M USD | +38.9% | +14.7% | 195.2% | |
| Peer median (excluding BBIO) | — | +27.8% | +16.0% | 55.1% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M |
| Cost of Revenue | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M |
| Gross Profit | 66.6M | 74.21M | 6.86M | 218.02M | 473.81M |
| Gross Margin | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| Research & Development | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M |
| Selling, General & Admin | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M |
| Operating Expenses | 643.23M | 586.42M | 614.23M | 811M | 1.04B |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| EBITDA | (533.83M) | (397.44M) | (565.47M) | (436.83M) | (676.45M) |
| EBITDA Margin | -765.7% | -511.9% | -6078.3% | -196.9% | -134.7% |
| Operating Income | (576.63M) | (512.2M) | (607.37M) | (592.97M) | (569.09M) |
| Operating Margin | -827.1% | -659.6% | -6528.8% | -267.2% | -113.3% |
| Interest Income | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M |
| Interest Expense | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M |
| Other Income / Expenses | (9.82M) | 27.55M | (45.88M) | 50.78M | (165.9M) |
| Income Before Tax | (586.45M) | (484.65M) | (653.25M) | (542.19M) | (734.99M) |
| Pre-Tax Margin | -841.2% | -624.2% | -7021.9% | -244.3% | -146.4% |
| Income Tax Expense | 0 | 0 | 0 | 1.15M | 555K |
| Net Income | (562.54M) | (481.18M) | (643.2M) | (535.76M) | (729.31M) |
| Net Margin | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (Basic) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| EPS (Diluted) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| Weighted Avg Shares | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
| Weighted Avg Shares (Diluted) | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.